← Back to Search

Tyrosine Kinase Inhibitor

Treatment (Crizotinib) for Lymphoma

Phase 2

Waitlist Available

Led By David S Hong

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

"This trial is testing how effective crizotinib is in treating patients with specific genetic changes in their cancers. Crizotinib is a type of medication that blocks enzymes that help cancer cells

Who is the study for?

This trial is for patients with various types of cancer, such as lymphoma and solid tumors, that have a specific genetic change called MET exon 14 deletion. The exact eligibility criteria are not provided but typically include factors like age, overall health status, and the stage of cancer.Check my eligibility

What is being tested?

The trial is testing Crizotinib's effectiveness on cancers with MET exon 14 deletion. It's a phase II study to see if this tyrosine kinase inhibitor can stop cancer cells from growing by blocking certain enzymes and cutting off blood supply to tumors.See study design

What are the potential side effects?

While specific side effects for Crizotinib in this trial aren't listed here, common ones may include vision problems, nausea, diarrhea, liver issues, lung inflammation (pneumonitis), heart problems and swelling due to fluid retention.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective response rate (ORR)

Secondary outcome measures

6-month progression-free survival (PFS) rate

Overall survival (OS)

Progression free survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (Crizotinib)Experimental Treatment4 Interventions

Patients receive crizotinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Biopsy

2014

Completed Phase 4

~1090

Crizotinib

2014

Completed Phase 3

~2370

Biospecimen Collection

2004

Completed Phase 2

~1700

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor

13,675 Previous Clinical Trials

40,926,942 Total Patients Enrolled

1,383 Trials studying Lymphoma

382,366 Patients Enrolled for Lymphoma

David S HongPrincipal InvestigatorECOG-ACRIN Cancer Research Group

6 Previous Clinical Trials

245 Total Patients Enrolled

1 Trials studying Lymphoma

50 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available vacancies for potential participants in this research study?

"According to the information on clinicaltrials.gov, patient recruitment for this particular trial is not ongoing. The study's initial posting was on May 30th, 2016, and its latest modification occurred on April 10th, 2024. Although this specific trial isn't actively seeking participants currently, there are a substantial number of 4884 other trials that are presently open for enrollment."

Answered by AI

Has the drug Crizotinib been officially sanctioned by the FDA for treatment purposes?

"Based on our evaluation at Power, the safety rating for Treatment (Crizotinib) is 2 out of 3. This assessment is due to ongoing Phase 2 trial data demonstrating some level of security but lacking evidence of effectiveness."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

2016. "Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06360575.